Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2000-01-24
2002-03-05
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
06353024
ABSTRACT:
FIELD OF THE INVENTION
The field of the invention is related to methods for preventing and/or treating inflammatory somatic pain and chronic pain. More particularly the invention concerns the use of trimebutine [2-dimethylamino-2-phenylbutyl 3,4,5-trimethoxybenzoate hydrogen maleate] for preventing and/or treating inflammatory somatic pain as well as chronic pain.
BACKGROUND OF THE INVENTION
Trimebutine [2-dimethylamino-2-phenylbutyl 3,4,5- trimethoxybenzoate hydrogen maleate; TMB] has been used in many countries since 1969 for the treatment of functional bowel disorders, including irritable bowel syndrome (IBS). The efficacy of the compound to relieve abdominal pain has been demonstrated in various clinical studies using different protocols of treatment (Lüttecke, 1980; Moshal and Herron, 1979, Toussaint et al., 1981; Ghidini et al. 1986). Trimebutine was found to display weak agonist activity for rat brain and guinea-pig (Roman et al., 1987) or canine (Allescher et al., 1991) intestinal opioid receptors, without selectivity for any of the &mgr;-, &dgr;- and &kgr;-subtypes. This weak activity was confirmed when using isolated intestinal fragments under transmural stimulation (Pascaud et al., 1987). This property could be responsible for the modulatory action of trimebutine on intestinal motility in fasted dog. Trimebutine given either intravenously or orally delays the appearance of a phase III of the migrating motor complex (MMC) in the stomach and the duodenum by inducing a premature phase III, migrating along the whole intestine (Bueno et al., 1987). In man, trimebutine stimulates intestinal motility in both fed and fasted states (Grandjouan et al., 1989). Furthermore, trimebutine reverses the effect of stress in jejunal motility (Delis et al., 1994).
More recently, trimebutine has been shown to be able to influence the activity of visceral afferents by decreasing the intensity of the recto-colonic reflex in rats as evidenced by the inhibition of colonic motility consecutive to rectal distension (Julia et al., 1996). This result may be related to the beneficial effects found with trimebutine in patients with IBS and more specifically in the treatment of attacks of abdominal pain.
There is a general agreement (9
th
World Congress on Pain, Vienna, August 1999) that there is an unmet medical need for the treatment of chronic pain. NSAIDs and opiates are ineffective in many cases. Antidepressants are being used with inconsistent eficacy (50-60%). Certain anticonvulsants (carbamazepine, clonazepam, baclofen) may be active. In extreme cases, capsaicin and local anesthetics are being tried. However, none of these approaches is satisfactory and some patients are refractory to all of them. In some cases like trigeminal neuralgia, neurosurgery (differential thermocoagulation of Gasser ganglion) remains the only way of alleviating pain.
From a starting point in visceral pain, the inventors found, as confirmed in the present application, that trimebutine has an inhibitory action on glutamate release through the blockade of sodium channels. More particularly, they found that the inhibition of glutamate release follows a presynaptic mechanism of action even though the opioid properties of trimebutine are not involved in this mechanism. In addition, as shown through results obtained in certain in vivo models and more particularly in models of hyperalgesia and chronic pain, they demonstrate that trimebutine can have an action on pain conditions other than visceral pain. This confirmes that trimebutine is useful in the treatment and/or the prevention of hyperalgesia and chronic pain as well as inflammatory somatic pain.
SUMMARY OF THE INVENTION
The invention relates to the use of trimebutine [2-dimethylamino-2-phenylbutyl-3,4,5-trimethoxy-benzoate hydrogen maleate] or its corresponding stereoisomers for the preparation of a medicament to prevent and/or treat inflammatory somatic pain and chronic pain. For the present invention, trimebutine is administered orally or by injection and preferably by intravenous injection at a dosage between 50 to 900 mg/day (patient with average weight of 70 kg) and preferentially between 300 to 600 mg/day. Particular embodiments of the invention provide the use of trimebutine or its stereoisomers for the preparation of medicaments useful for preventing and/or treating inflammatory somatic pain (for example arthritis, polyarthritis, spondylarthritis) and chronic pain conditions (for example neurological pain, osteo-traumatic pain, back pain, cancer pain, neuralgias including post-zosterian neuralgia). Specific embodiments concern a method for preventing and/or treating inflammatory somatic pain and/or chronic pain comprising administering trimebutine to a patient in need thereof
REFERENCES:
patent: 2.369 (1962-10-01), None
patent: 99/01417 (1999-02-01), None
Ma et al, Chemical Abstracts, vol. 132, abstract No. 117407, 1999.*
Lecheze et al, Chemical Abstracts, vol. 129, abstract No. 285931, 1998.*
Schaffstein et al, Biological Abstracts, vol. 89, abstract No. 74779, 1990.*
Allescher, et al. Interaction of Trimebutine and JO-1196 (fedotozine) with Opioid Receptors in the Canine Ileum,J. Parmacol. Exp. Ther., vol. 257, No. 2, 1991, pp, 836-842.
Attal, et al., “Further Evidence for ‘Pain-Related’ behaviors in a Model of Unilateral Peripheral Mononeuropathy”,Pain, vol. 41, 1990, pp. 235-251.
Bennett, et al., “A Peripheral Mononeuropathy in Rat that Produces Disorders of Pain Sensation Like Those Seen In Man”,Pain, vol. 33, 1988, pp 87-107.
Berge, et al., “Pharmaceutical Salts”,J. Pharm. Sci., vol. 66, No. 1, Jan. 1977, pp 1-19.
Bueno, et al., “Effects of Orally vs. Parenterally administrated Trimebutine on Gastrointestinal and Colonic Motility in Dogs”,Gastroenterol Clin. Biol., vol. 11, 1987, pp. 90B-93B.
Calcutt, et al., “Tactile Allodynia and Formalin Hyperalgesia in Streptozotocin-Diabetic Rats: Effects of Insulin, Aldose Reductase Inhibition and Lidocaine”,Pain, vol. 68, 1996, pp 293-299.
Cheng, et al., “Relationship Between the Inhibition Constant (Kr) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (150) of an Enzymatic Reaction”,Biochem. Parmacol., vol. 22, 1973, pp 3099-3108.
Courteix, et al., “Streptozocin-Induced Diabetic Rats: Behavioural Evidence for a Model of Chronic Pain”,Pain, vol. 53, 1933, pp 81-83.
Delis, et al., “The Effect of Stress and an Opioid Agonist on Postprandial Motor Activity in the Human Small Bowel”,Gastroenterology, vol. 106, 1994, p A485 (Abstract Only).
Dickenson, A.H., “Spinal Cord Pharmacology of Pain”,British J. Anesthesia, vol. 75, 1995, pp 193-200.
Ghidini, et al., “Single Drug Treatment for Irritable Colon: Rociverine Versus Trimebutine Maleate”,Curr. Ther. Res., vol. 39, No. 4, Apr. 1985, pp 541-548.
Grandjouan, et al., “A Comparison of Metoclopramide and Trimebutine on Small Bowel Motility in Humans”,Aliment. Pharmacol. Ther., vol. 3, 1989, pp 387-393.
Julia, V. et al., “Influence de la trimebutine (Debridat) sur l'hypomotricite colique et les crampes abdominales liees a la distension rectale chez le rat”,Med. Chir. Dig., vol. 25, 1996, pp 239-242.
Lees, et al., “Studies on the Mechanism of Action of the Novel Anticonvulsant Lamotrigine (Lamictal) Using Primary Neuroglial Cultures from Rat Cortex”,Brain Res., vol. 612, pp 190-199.
Luttecke, K., “A three-part Controlled Study of Trimebutine in the Treatment of Irritable Colon Syndrome”,Cur. Med. Res. Op., vol. 6, No. 6, 1980, pp 437-443.
Matteson et al., “Na and Ca Channels in a Transformed Line of Anterior Pituitary Cells”,J. Gen. Physiol., vol. 83, 1984, pp 371-394
McPherson, G. A., “Analysis of Radioligand Binding Experiments”,J. Pharmacol. Methods, vol. 14, 1985, pp 213-228.
Moshal, et al., “A Clinical Trial of Trimebutine (Mebutin) in Spastic Colon”,J. Int. Med. Res., vol. 7, 1979, pp 231-234.
Nagasaki, et al., “Effect of Trimebutine on Voltage-activated Calcium Currents in Rabbit Ileal Smooth Muscle Cells”,Br. J. Pharmacol, vol. 110, 1993, pp 399-403.
Nagasaki, et al., “Effect of Trimebutine on K+ Cur
Brunelle Gilles
Grouhel Agnes
Hamon Jacques
Roman François
Ashbrook Charles W.
Jarvis William R. A.
Warner-Lambert & Company
LandOfFree
Method for preventing and treating arthritis,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing and treating arthritis,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing and treating arthritis,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2872168